Back to Home
Video

Module 4: Tackling The Target. Session II

Release Date

April 30, 2026

Expiration Date

May 1, 2027

Credits

1.0 CME, NCPD

Specialties

Lung Cancer, Medical Oncology+4 more

Activity Overview

This educational activity is an archive of the live conference held from January 23 to 25, 2026.

Target Audience

This educational activity is intended for oncologists involved in the treatment and management of patients with lung cancer. Nurse practitioners, nurses, physician assistants, pharmacists, clinical investigators, fellows, and other health care professionals interested in the treatment of lung cancer may also participate.

Learning Objectives

  • Evaluate efficacy and safety data from recent clinical trials on established and emerging therapeutic approaches for lung cancer.
  • Integrate the latest clinical evidence and guideline recommendations into the development of personalized treatment plans for patients with lung cancer
  • Implement best practices to identify, prevent, and manage treatment-related adverse effects associated with novel therapies for lung cancer.
          Module 4: Tackling The Target. Session II

          GET STARTED WITH THIS PROGRAM:

          Register now to gain access to this program.

          Create AccountAlready Registered? Login Here

          Accreditation/Credit Designation

          Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

          Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

          Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

          Acknowledgment of Commercial Support

          This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Exact Sciences Corp; Merck Sharp & Dohme LLC; Partner Therapeutics, Inc; and Revolution Medicines.

          Follow Us on Social Media!

          Related Content

          Course

          Module 4: Tackling The Target. Session II

          Create Account